Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study examines Igalmi's effects after repeated use for agitation

NCT ID NCT06041646

First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 27 times

Summary

This study looked at how the body builds tolerance to Igalmi (a fast-acting medicine for agitation) and what happens when it's stopped. It involved 29 adults with schizophrenia or bipolar disorder who had frequent agitation. Researchers measured changes in agitation levels and watched for side effects during a 3-day follow-up period.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • BioXcel Clinical Research Site

    Little Rock, Arkansas, 72211, United States

  • BioXcel Clinical Research Site

    Rogers, Arkansas, 72758, United States

Conditions

Explore the condition pages connected to this study.